The Top Line Inside the sterile fill capacity crunch (Sponsored)
Feb 23, 2026
Denis Johnson, CEO of Grand River Aseptic Manufacturing with 25+ years in GMP sterile fill operations. He talks about a U.S. sterile manufacturing capacity crunch and why companies are reshoring. He covers the industry shift to isolator technology driven by Annex 1 and why segmentation and specialization matter. He also outlines GRAM’s investments in new facilities, high-volume syringe and cartridge capabilities.
AI Snips
Chapters
Transcript
Episode notes
U.S. Sterile Fill Capacity Is Tightening
- U.S. sterile fill capacity is tightening due to acquisitions, reshoring, and a shift toward isolator technology.
- Denis Johnson cites Novo Nordisk's acquisition of Catalent Bloomington and growing preference for isolators under Annex 1 as drivers of limited U.S. capacity.
CDMO Market Is Segmenting By Volume And Mix
- The CDMO market is segmenting by capability needs: high-volume low-mix versus high-mix biologics and launch-focused services.
- Johnson explains GLP-1s and COVID drugs require different CDMOs than high-mix biologics because of volume and tech-transfer demands.
People Expertise Outweighs Equipment As Barrier
- Expertise and compliance know-how are higher barriers to entry than equipment purchase in sterile fill.
- Johnson warns that operating on the edge of capability leads to compliance trouble; people skills, not machinery, will bottleneck fills.